Abstract
Overall survival (OS) is the standard endpoint in oncology trials but often requires prolonged follow-up. Event-free survival (EFS) is a well-accepted endpoint in early-stage oncology trials and a common surrogate endpoint for OS in neoadjuvant and adjuvant cancer therapy. This study aims to evaluate the trial-level association between EFS and OS for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma in neoadjuvant/adjuvant settings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
